Source: Novavax, Inc.
Novavax to Highlight RSV Program Data at Two Upcoming Meetings
GAITHERSBURG, Md., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX) today announced that its representatives will share data from its RSV F vaccine program via oral and poster presentations at IDWeek 2018 in San Francisco, California, taking place October 3-7 and at the 11th International Respiratory Syncytial Virus Symposium in Asheville, North Carolina, taking place October 31-November 4.
Oral presentation details are as follows:
| IDWeek 2018 Meeting | ||
| Title: | Progress Toward a Vaccine for Maternal Immunization to Prevent Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Illness (LRTI) in Infants | |
| Presenter: | Louis F. Fries III, M.D., Senior Vice President and Chief Medical Officer, Novavax, Inc. | |
| Session: | 213. Late Breaker Oral Abstracts: Influenza and Vaccines | |
| Date and Time: | Saturday, October 6, 11:20 a.m. P.T. | |
| Location: | Moscone Convention Center S 152-154 | |
| 11th International Respiratory Syncytial Virus Symposium | ||
| Title: | Magnitude and Durability of Anti-F IgG and Palivizumab-Competitive Antibody (PCA) Responses One Year Following Immunization with RSV F Nanoparticle Vaccine Adjuvanted with Aluminum Phosphate, or a Novel Adjuvant | |
| Presenter: | Vivek Shinde, M.D., M.P.H., Executive Director, Clinical Development, Novavax, Inc. | |
| Session: | 5. Advancements in RSV Vaccines | |
| Date and Time: | Thursday, November 1, 4:45 p.m. – 6:15 p.m. E.T. | |
| Location: | Omni Grove Park Inn | |
| Title: | Progress Toward a Vaccine for Maternal Immunization to Prevent Respiratory Syncytial Virus Lower Respiratory Tract Illness (RSV LRTI) in Infants | |
| Presenter: | Louis F. Fries III, M.D., Senior Vice President and Chief Medical Officer, Novavax, Inc. | |
| Session: | 12. Maternal Immunity & Maternal Vaccination | |
| Date: | Saturday, November 3, 3:00 p.m. – 4:30 p.m. E.T. | |
| Location: | Omni Grove Park Inn | |
Poster presentations for the 11th International Respiratory Syncytial Virus Symposium will occur on Thursday, November 1, 11:30 a.m. – 12:30 p.m. E.T. and on Friday, November 2, 8:30 p.m. – 10:00 p.m. E.T. at the Omni Grove Park Inn.
| Title: | Feasibility Evaluation of Blow Fill Seal Process and Compatibility with Aluminum Phosphate Adjuvanted Recombinant RSV F Nanoparticle Vaccine for Maternal Immunization | |
| Presenter: | Yen-Huei Lin, Ph.D., Senior Director, Formulation and Drug Product Development, Novavax, Inc. | |
| Title: | Binding Kinetics of RSVF Prefusogenic Vaccine to Palivizumab and Serum Polyclonal Antibody | |
| Presenter: | Hanxin Lu, Ph.D., Principal Scientist, Novavax, Inc. | |
| Title: | In-depth Analytical Characterization and Structural Modeling of Novavax RSV F Nanoparticle Vaccine | |
| Presenter: | Ernest Maynard, Ph.D., Principal Scientist, Analystical Development, Novavax, Inc. | |
| Title: | Antigenic Characterization Prefusogenic Nanoparticle Vaccine, Prefusion, and Postfusion F against a Broad Range of Neutralizing Monoclonal Antibodies and Epitope Responses in Cotton Rats | |
| Presenter: | Nita Patel, Director, Antibody Discovery, Vaccine Development Novavax, Inc. | |
| Title: | Respiratory Syncytial Virus (RSV) Prefusogenic F Nanoparticle Vaccine Compared to Prefusion and Postfusion RSV F: Physical and Antigenic Structure, Immunogenicity, and Protection | |
| Presenter: | Gale Smith, Ph.D., Vice President, Vaccine Development, Novavax, Inc. |
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that drives improved health globally through the discovery and development of innovative vaccines to prevent serious respiratory diseases. ResVax™, its RSV vaccine for infants via maternal immunization, is the only vaccine in a Phase 3 clinical program and is poised to help prevent the second leading cause of death in children under one year of age worldwide. Novavax is also advancing NanoFlu™, its quadrivalent influenza nanoparticle vaccine, to address key factors that can lead to the poor effectiveness of currently approved flu vaccines. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic nanoparticles addressing urgent global health needs.
For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.
Investors
Novavax, Inc.
Erika Trahan
Senior Manager, Investor & Public Relations
ir@novavax.com
240-268-2000
Westwicke Partners
John Woolford
john.woolford@westwicke.com
443-213-0506
Media
Sam Brown
Mike Beyer
mikebeyer@sambrown.com
312-961-2502